Solara Active Pharma Sciences per share figures

Share price at each year-end
Tap a line for its trendCurrentlast 12MFY26Mar 2026FY25Mar 2025FY24Mar 2024FY23Mar 2023FY22 and earlierAlpha Plus
₹7.66−₹1.68₹0.14−₹157.62−₹6.16
FY22 and earlierEvery year the company has filed comes with Alpha Plus.
₹7.66−₹1.68₹0.14−₹157.62−₹6.16
₹281.48₹281.48₹271.86₹259.37₹416.73
₹344.92₹307.57₹318.95₹358.03₹401.06
—₹34.35₹52.87₹30.24₹43.40
₹22.49₹22.49₹42.95₹18.84₹12.48
4.54.54.03.63.6
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SOLARA₹653.80

Solara Active Pharma Sciences Limited

· Pharma & Health
₹ CrorePeersINDSWFTLABDCALSMSPHARMAHIKALPANACEABIOSAIPARENTINDOCOUNICHEMLABMcap ₹2,910 Cr
HighlightsEnterprise ValueMultiplesPer ShareAnnuals · FY-end closes
₹ per share
12 Months Ending
FY23
31/03/2023
FY24
31/03/2024
FY25
31/03/2025
FY26
31/03/2026
Current/LTM
TTM · last close
Basic EPS-6.16-157.620.14-1.687.66
Diluted EPS-6.16-157.620.14-1.687.66
Book Value per Share416.73259.37271.86281.48281.48
Revenue per Share401.06358.03318.95307.57344.92
Cash Flow per Share43.4030.2452.8734.35—
Free Cash Flow per Share12.4818.8442.9522.4922.49
Shares Outstanding (cr)3.63.64.04.54.5
Market Cap/EV/multiples pair each (split/bonus-adjusted) FY-end close with the latest filed share count; Current column uses the last close. Market Capitalization is a market-level figure — identical across Consolidated/Standalone (the accounting rows below differ). No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.